Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Inclusion Criteria: DISEASE CHARACTERISTICS: * Histologically confirmed invasive mammary carcinoma * Stage IV disease * No locally recurrent breast cancer * Patients with HER2/neu overexpressing tumors must have received prior trastuzumab (Herceptin®) in first-line treatment of metastatic breast cancer * Patients with estrogen receptor- or progesterone receptor-expressing tumors must have received prior endocrine therapy (i.e., aromatase inhibitors, fulvestrant, tamoxifen, or ovarian ablation) in first-line treatment of metastatic breast cancer * No symptomatic brain metastases * Patients with a history of brain metastases must be clinically stable and not taking steroids or therapeutic anticonvulsants that are CYP3A4 modifiers * Patients with asymptomatic brain metastases on prophylactic convulsants that are CYP3A4 modifiers are not eligible * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Menopausal status not specified * ECOG performance status 0-1 * Life expectancy ≥ 6 months * ANC ≥ 1000/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Creatinine ≤ 1.5 times upper limit of normal (ULN) * Bilirubin ≤ 1.5 times ULN (3 times ULN if liver metastasis present) * SGOT and SGPT ≤ 1.5 times ULN (3 times ULN if liver metastasis present) * Alkaline phosphatase ≤ 3 times ULN if liver metastasis present * Able to swallow and retain oral medication * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after completion of study treatment * Must be disease-free from prior invasive cancers for \> 5 years with the exception of completely resected basal cell or squamous cell carcinoma of the skin or successfully treated cervical carcinoma in situ * No malabsorption syndrome, disease significantly affecting gastrointestinal function, or ulcerative colitis * No uncontrolled intercurrent illness including, but not limited to: * Ongoing or active infection requiring parenteral antibiotics * Impairment of lung function (i.e., chronic obstructive pulmonary disease or lung conditions requiring oxygen therapy) * Symptomatic New York Heart Association class III-IV congestive heart failure * Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within the past 6 months * Uncontrolled hypertension (systolic blood pressure \[BP\] \> 180 mm Hg or diastolic BP \> 100 mm Hg) * Clinically significant cardiac arrhythmia (i.e., multifocal premature ventricular contractions, bigeminy, trigeminy, or ventricular tachycardia that is symptomatic or requires treatment) * Uncontrolled diabetes * Psychiatric illness/social situations that would preclude compliance with study requirements * No known history of uncontrolled or symptomatic neuropathy ≥ grade 2 * No hypersensitivity to paclitaxel, or drugs using the vehicle Cremophor, Chinese hamster ovary cell products, or other recombinant human antibodies Exclusion Criteria: PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Recovered from all prior treatment * Must not have exceeded a total cumulative dose of life-time exposure of doxorubicin hydrochloride ≤ 360 mg/m² or epirubicin hydrochloride ≤ 640 mg/m² * At least 2 weeks since other prior investigational drugs * No prior resection of the stomach or small bowel * No more than 4 prior chemotherapy regimens in the metastatic setting * This restriction does not include endocrine therapies or single agent biologic therapies (i.e., trastuzumab) * Concurrent radiotherapy to painful bone metastases or areas of impending bone fracture allowed as long as radiotherapy is initiated prior to study entry * No concurrent trastuzumab * No concurrent endocrine therapy * No concurrent CYP3A4 modifiers * No concurrent herbal supplement * No other concurrent anticancer therapy (chemotherapy, radiotherapy, surgery, immunotherapy, hormonal therapy, or biological therapy)